Alvogen is the next generation pharmaceuticals company. Its business model ensures competitive advantage through focused in-house capabilities and a network of partners for enhanced speed and flexibility. Alvogen currently has commercial operations in 34 countries around the globe, with regional hubs based in North America, Romania and Taiwan.
Alvogen's product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology in addition to a fast growing portfolio of biosimilars and OTC products.
Alvogen is already well advanced in the field of biopharmaceuticals and currently markets several biosimilars in selected regions through strategic alliances. Over $500 million are being invested in the development of monoclonal antibodies and state-of-the-art manufacturing capabilities.